['myocardial infarction']
['ticagrelor 90 mg', 'ticagrelor 60 mg']

        Inclusion Criteria:

          -  provision of informed consent prior to any study specific procedures

          -  diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment
             elevation myocardial infarction according to the Third Universal Definition of
             Myocardial Infarction

          -  index event treatment with percutaneous coronary intervention

          -  male or non-pregnant female, aged 18-80 years old

        Exclusion Criteria:

          -  contraindications for ticagrelor

          -  further coronary revascularization planned during the first 45 days after myocardial
             infarction

          -  indications for chronic treatment with oral anticoagulant or low-molecular-weight
             heparin

          -  active bleeding

          -  history of intracranial hemorrhage

          -  recent gastrointestinal bleeding (within 30 days)

          -  history of coagulation disorders

          -  history of moderate or severe hepatic impairment

          -  history of major surgery or severe trauma (within 3 months)

          -  active neoplastic disease

          -  patient requiring dialysis

          -  chronic inflammatory disease

          -  current therapy with strong CYP3A inhibitors or strong CYP3A inducers
      